Cencora, Inc. $COR Shares Sold by Isthmus Partners LLC

Isthmus Partners LLC decreased its stake in shares of Cencora, Inc. (NYSE:COR) by 5.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 56,787 shares of the company’s stock after selling 3,148 shares during the period. Cencora accounts for 2.1% of Isthmus Partners LLC’s portfolio, making the stock its 7th largest position. Isthmus Partners LLC’s holdings in Cencora were worth $19,180,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vestcor Inc increased its position in Cencora by 0.5% during the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock worth $1,624,000 after purchasing an additional 28 shares during the last quarter. JFS Wealth Advisors LLC increased its position in Cencora by 30.2% during the fourth quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock worth $42,000 after purchasing an additional 29 shares during the last quarter. Cornerstone Wealth Group LLC increased its position in Cencora by 1.3% during the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after purchasing an additional 30 shares during the last quarter. Apollon Wealth Management LLC increased its position in Cencora by 0.5% during the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock worth $2,205,000 after purchasing an additional 30 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC increased its position in Cencora by 31.4% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company’s stock worth $43,000 after purchasing an additional 33 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a research report on Monday, May 4th. William Blair began coverage on shares of Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating for the company. Wells Fargo & Company decreased their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research note on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Citigroup decreased their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Price Performance

COR opened at $256.96 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a 50 day moving average of $314.65 and a two-hundred day moving average of $339.22. The company has a market cap of $49.99 billion, a P/E ratio of 19.71, a P/E/G ratio of 1.20 and a beta of 0.64.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the prior year, the firm earned $4.42 earnings per share. Cencora’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts expect that Cencora, Inc. will post 17.76 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be paid a $0.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.